Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis-Reference-Cited by-同舟云学术

Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis

Published:2020-02 Issue:1 Volume:44 Page:100502
ISSN:0147-0272
Container-title:Current Problems in Cancer
language:en
Short-container-title:Current Problems in Cancer

Author:

Jiang Shiyu,Zhen Hongnan,Jiang Hongxin

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Cancer Survivorship, Atlanta (GA): Center for disease Control and Prevention (US), national Center for Chronic disease Prevention and health Promotion. http://www.cdc.gov/cancer/survivorship/pdf/survivorship_fs.pdf(Accessed 23 May 2018).

2. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised con- trolled trial by the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

3. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2011

4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

5. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy;Blood Advances;2024-05-16

2. Specific mortality in patients with diffuse large B-cell lymphoma: a retrospective analysis based on the surveillance, epidemiology, and end results database;European Journal of Medical Research;2024-04-20

3. Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma;ESMO Open;2024-02

4. Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin’s lymphoma patients in England;Leukemia Research;2023-04

5. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659);Oncotarget;2023-01-26